Recent Press Releases
| Source: XORTX Therapeutics Inc.
CALGARY, Alberta, July 14, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Mr.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
● Dr. Haworth Appointed Chief Medical Officer ●
CALGARY, Alberta, June 30, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr.
Recent Press Releases
CALGARY, Alberta, June 17, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Jacqueline Le Saux to the Company’s board of directors and the resignation of Allan Williams.
Recent Press Releases
CALGARY, Alberta, May 13, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Mr.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
CALGARY, Alberta, April 06, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to announce that it has received notification of intention to grant the patent “Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office for this PCT international application.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
CALGARY, Alberta, March 16, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Zoom with LD Mirco to be held virtually on March 18, 2021.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
CALGARY, Alberta, March 09, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Sachs 14th Annual European Life Sciences CEO Forum 2021 to be held virtually March 10th and 11th, 2021.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
● Compositions and Methods for Enhancing Anti-viral Therapies ●
CALGARY, Alberta, March 08, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the filing of a new provisional patent application entitled “Compositions and Methods for Enhancing Anti-Viral Therapies”.
Recent Press Releases
CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that 4,286,438 warrants that were issued in connection with the February 2020 private placement and expired February 28, 2021 have been exercised for aggregate proceeds of $1,037,524.
Recent Press Releases
| Source: XORTX Therapeutics Inc.
CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that 4,286,438 warrants that were issued in connection with the February 2020 private placement and expired February 28, 2021 have been exercised for aggregate proceeds of $1,037,524.